# Referencat

* http://apps.who.int/medicinedocs/pdf/s6164e/s6164e.pdf
* archives.who.int/tbs/tbs2004/Seminar1/022-Pharmacovigilance.ppt
* http://ec.europa.eu/health/files/eudralex/vol-1/dir\_2001\_83\_cons2009/2001\_83\_cons2009\_en.pdf
* [www.cioms.ch](http://www.cioms.ch)
* <http://www.druglib.com/druginfo/prozac/interactions_overdosage_contraindications/>
* http://www.ema.europa.eu/docs/en\_GB/document\_library/Scientific\_guideline/2012/06/WC500129131.pdf
* <http://www.eudravigilance.org/highres.htm>
* [www.farmacovigilanza.org](http://www.farmacovigilanza.org/)
* <http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm>
* [www.ich.org](http://www.ich.org/)
* <http://www.ncbi.nlm.nih.gov/gene/1565>
* <http://www.who.int/medicines/areas/quality_safety/safety_efficacy/advdrugreactions/en/>
* http://apps.who.int/medicinedocs/pdf/s6164e/s6164e.pdf
* archives.who.int/tbs/tbs2004/Seminar1/022-Pharmacovigilance.ppt
* http://ec.europa.eu/health/files/eudralex/vol-1/dir\_2001\_83\_cons2009/2001\_83\_cons2009\_en.pdf
* [www.cioms.ch](http://www.cioms.ch/)
* <http://www.druglib.com/druginfo/prozac/interactions_overdosage_contraindications/>
* http://www.ema.europa.eu/docs/en\_GB/document\_library/Scientific\_guideline/2012/06/WC500129131.pdf
* <http://www.eudravigilance.org/highres.htm>
* [www.farmacovigilanza.org](http://www.farmacovigilanza.org/)
* <http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm>
* [www.ich.org](http://www.ich.org/)
* <http://www.ncbi.nlm.nih.gov/gene/1565>
* <http://www.who.int/medicines/areas/quality_safety/safety_efficacy/advdrugreactions/en/>
* http://apps.who.int/medicinedocs/pdf/s6164e/s6164e.pdf
* archives.who.int/tbs/tbs2004/Seminar1/022-Pharmacovigilance.ppt
* http://ec.europa.eu/health/files/eudralex/vol-1/dir\_2001\_83\_cons2009/2001\_83\_cons2009\_en.pdf
* [www.cioms.ch](http://www.cioms.ch/)
* <http://www.druglib.com/druginfo/prozac/interactions_overdosage_contraindications/>
* http://www.ema.europa.eu/docs/en\_GB/document\_library/Scientific\_guideline/2012/06/WC500129131.pdf
* <http://www.eudravigilance.org/highres.htm>
* [www.farmacovigilanza.org](http://www.farmacovigilanza.org/)
* <http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm>
* [www.ich.org](http://www.ich.org/)
* <http://www.ncbi.nlm.nih.gov/gene/1565>
* <http://www.who.int/medicines/areas/quality_safety/safety_efficacy/advdrugreactions/en/>
* <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1312247/>
* <http://nursinglink.monster.com/training/articles/320-clinically-significant-drug-interaction-with-the-cytochrome-p450-enzyme-system>
* DiPiro JT, editor. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford, Conn: Appleton & Lange; 1999. pp. 29–30.
* Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician. 1998;57:107–116.
* Goodman LS, Limbird LE, Milnoff PB, Gilman AG, Hardman JG, editors. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996. pp. 12–16.
* Belpaire FM, Bogaert MG. Cytochrome P450: genetic polymorphism and drug interactions. Acta Clinica Belgica. 1996;51:254–260.
* Nelson WE, editor. Textbook of Pediatrics. 15th ed. Philadelphia: WB Saunders Co; 1996. p. 1127.
* Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63:332–341.
* Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 1998;46:49–53.
* <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1312247/>
* <http://nursinglink.monster.com/training/articles/320-clinically-significant-drug-interaction-with-the-cytochrome-p450-enzyme-system>
* DiPiro JT, editor. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford, Conn: Appleton & Lange; 1999. pp. 29–30.
* Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician. 1998;57:107–116.
* Goodman LS, Limbird LE, Milnoff PB, Gilman AG, Hardman JG, editors. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996. pp. 12–16.
* Belpaire FM, Bogaert MG. Cytochrome P450: genetic polymorphism and drug interactions. Acta Clinica Belgica. 1996;51:254–260.
* Nelson WE, editor. Textbook of Pediatrics. 15th ed. Philadelphia: WB Saunders Co; 1996. p. 1127.
* Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63:332–341.
* Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 1998;46:49–53
* <http://www.sciencemuseum.org.uk/broughttolife/themes/traditions/herbalism.aspx>
* <http://www.axapharm.ch/pi_pdf_download/cimex_produkte/fluoxetin/pi_fluoxetin_cimex_alb.pdf>
* <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1934960/>
* <http://www.aafp.org/afp/2008/0601/p1553.html>
* <http://www.ncbi.nlm.nih.gov/pubmed/8473545>
* <http://www.aafp.org/afp/2003/1101/p1781.html>
* <http://www.ncbi.nlm.nih.gov/pubmed/21480949>
* Sullivan J.R., Shear N.H. The drug hypersensitivity syndrome: What is the pathogenesis? Archives of Dermatology, 2001, 137:357-364.
* Descamps V., Valance A., Edlinger C., et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Archives of Dermatology, 2001, 137:301-304.
* Eshki M., Allanore L., Musette P., Milpied B., Grange A., Guillaume J., Chosidow O., Guillot I. Paradis V., Joly P., Crickx B., Ranger-Rogez S., Descamps V. Twelve-Year Analysis of Severe Cases of Drug Reaction With Eosinophilia and Systemic Symptoms: A Cause of Unpredictable Multiorgan Failure. Archives of Dermatology, 2009; 145: 67-72.
* Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. New England Journal of Medicine, 1994, 331: 1272-1285.
* Br J Clin Pharmacol. 2010 November; 70(5): 749–755.
* Abrams, WB, Beers, MH. Clinical Pharmacology in an aging population. Clinical Pharmacology Therapeutics 1998:63:281-4.
* Beers, MH. Explicit criteria for determining potentially inappropriate medication use in the elderly. Archives of Internal Medicine 1997: 157: 1531-6.
* Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716-2724
* ISMP Medication Safety Alert, April 21, 2005, <http://www.ismp.org/MSAarticles/20050421.htm> Institute for Healthcare Improvement website includes a section on Medication Reconciliation Review, including samples of a reconciliation tracking tool and a medication reconciliation flowsheet, <http://www.ihi.org/>
* (Lehne, Richard A.. Pharmacology for Nursing Care, 6th Edition. W.B. Saunders Company, 062006. 11).
* J.D. Rozich, M.D., Ph.D., M.B.A., "Standardization as a Mechanism to Improve Safety in Health Care," Joint Commission Journal on Quality and Safety, Volume 30, Number 1, January 2004, pages 5-14
* Br J Clin Pharmacol. 2010 November; 70(5): 749–755.
* <http://depts.washington.edu/druginfo/Formulary/Pregnancy.pdf>
* [http://www.empr.com/drugs-contraindicated-in-pregnancy/article/125914/#](http://www.empr.com/drugs-contraindicated-in-pregnancy/article/125914/)
* [http://bmb.oxfordjournals.org/content/83/1/259.full#](http://bmb.oxfordjournals.org/content/83/1/259.full)